SCHEMBL140150

SCHEMBL140150

N#Cc1ccc2c(c1)OCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
USP2 O75604 1/20 0.49
CYP3A4 P08684 1/20 0.48
PDE5A O76074 2/20 0.47
ALDH1A1 P00352 3/20 0.46
GSK3A P49840 3/20 0.46
GSK3B P49841 3/20 0.46
HSD17B10 Q99714 3/20 0.45
ALOX15 P16050 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45
KMT2A Q03164 1/20 0.45
AURKA O14965 1/20 0.45
CSNK1E P49674 1/20 0.45
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30300332 1.00 MAPT (0.51) MAPTSMN1; SMN2USP2CYP3A4PDE5A
Ammonia Solution, Strong SCHEMBL3942500 0.91 MAPT (0.46) MAPTSMN1; SMN2USP2CYP3A4PDE5A
SCHEMBL943860 0.87 PKM (0.54) MAPTSMN1; SMN2USP2ALDH1A1GSK3A
SCHEMBL10415830 0.82 CYP2A6 (0.43) MAPTSMN1; SMN2USP2PDE5AALDH1A1
SCHEMBL16199534 0.82 MAPT (0.53) MAPTSMN1; SMN2USP2ALDH1A1GSK3A
SCHEMBL31739246 0.80 GSK3A (0.51) MAPTSMN1; SMN2CYP3A4PDE5AGSK3A
SCHEMBL5098907 0.79 BCL2L1 (0.52) MAPTSMN1; SMN2USP2ALDH1A1GSK3A
SCHEMBL5091184 0.79 MAPT (0.49) MAPTSMN1; SMN2USP2ALDH1A1GSK3A
SCHEMBL97197 0.78 NPC1 (0.48) MAPTSMN1; SMN2CYP3A4ALDH1A1HSD17B10
SCHEMBL9432285 0.78 CYP3A4 (0.48) MAPTSMN1; SMN2CYP3A4ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4679087-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
WO-2024190663-A1 BIOMARKER AND USE THEREOF 株式会社明治 2024-09-19 WO claimed
CN-113024530-B Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof 合肥工业大学 2023-07-18 CN claimed
CN-110314692-B Heteropolyacid and method for synthesizing piperonyl nitrile by using heteropolyacid as catalyst 和德化学(苏州)有限公司 2022-04-05 CN claimed
CN-113024530-A Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof 合肥工业大学 2021-06-25 CN claimed
EP-2979682-A1 A fragrance composition Symrise AG (DE) 2016-02-03 EP claimed
US-20100104644-A1 Compositions and Methods for Treating or Preventing Ophthalmic Disease UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-04-29 US claimed
US-20090291919-A1 Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2009-11-26 US claimed
US-20090286808-A1 Opsin Stabilizing Compounds and Methods of Use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2009-11-19 US claimed
EP-2069391-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OPHTHALMIC DISEASE University of Florida Research Foundation, Inc. (US) 2009-06-17 EP claimed
US-6573397-B2 Chlorinating 3,4-methylenedioxybenzonitrile with sulfuryl chloride or chlorine in presence of promoter to form 2-chloro-benzo(1,3)dioxole-5-carbonitrile, hydrolyzing with water to produce 3,4-dihydroxybenzonitrile UBE INDUSTRIES, LTD. (JP) 2003-06-03 US claimed
WO-2003043976-A1 METHOD FOR PRODUCING 3,4-DIHYDROXYBENZONITRILE LONZA AG (CH) 2003-05-30 WO claimed
US-20030009048-A1 Process for producing 3,4-dihydroxybenzonitrile UBE INDUSTRIES, LTD. 2003-01-09 US claimed
EP-1270550-A1 Process for producing 3, 4-Dihydroxybenzonitrile Ube Industries, Ltd. (JP) 2003-01-02 EP claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291919-A1 Compositions and Methods for Treating or Preventing Ophthalmic Light Toxicity ALDH1A2, EYA3, PDE6C MAPT 1961/4885SMN1; SMN2 4664/4885USP2 1814/4885
US-20100104644-A1 Compositions and Methods for Treating or Preventing Ophthalmic Disease ALDH1A2, PDE6C, EYA3 MAPT 2030/4885SMN1; SMN2 3321/4885USP2 1853/4885
US-20030009048-A1 Process for producing 3,4-dihydroxybenzonitrile BPNT1, DCUN1D4, CPN1 MAPT 4834/4885SMN1; SMN2 4145/4885USP2 841/4885
US-20090286808-A1 Opsin Stabilizing Compounds and Methods of Use CRYZ, NR2E3, CRYAB MAPT 467/4885SMN1; SMN2 231/4885USP2 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.